Hopp til hovedinnhold

Mannlig hypogonadisme

Mannlig hypogonadisme skyldes nedsatt produksjon av kjønnshormonet testosteron. Det kan skyldes svikt i reguleringen fra hjernen eller sykdom i selve testiklene.

Sist revidert:

QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/barn/hormonsykdommer/hypogonadisme-mannlig/ 

Hva er gonader?

Hva er hypogonadisme?

Symptomer og tegn

Diagnostikk

Behandling

Prognose

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Mannlig hypogonadisme. Referanselisten for dette dokumentet vises nedenfor.

  1. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008;159:507-514. PubMed 
  2. Svartberg JB, Jørgensen AP, Haave EM, Finnes TE. Mannlig hypogonadisme. Nasjonal veileder i endokrinologi. Publisert 27.01.2019. Siden lest 21.05.2019. www.prosedyrer.no 
  3. Tajar A, Forti G, O'Neill TW, et al; EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study. J Clin Endocrinol Metab. 2010;95:1810-1818. PubMed 
  4. Buvat J, Lemaire A. endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158: 764-7. PubMed 
  5. Bodie J, Lewis JB, Schow D et al. Laboratory evaluations of erectile dysfunction: an evidence based approach. J Urol 2003; 169: 2262-4. PubMed 
  6. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363: 123-35. pmid:20554979 PubMed 
  7. Svendsen K-OB, Schultz A. Seksuell dysfunksjon hos menn. Tidsskr Nor Legeforen 2008; 128: 448-52. Tidsskrift for Den norske legeforening 
  8. Smith HS, Elliot JA. Opioid-induced androgen deficiency (OPIAD). Pain Physician 2012; 15: 145-56. pmid:22786453 PubMed 
  9. Andersen M, Arntsen SA, Eriksen EF, et al. Hypogonadisme. Norsk urologisk forenings anbefalinger for allmennleger 2013.
  10. Grant NN, Anawalt BD. Male hypogonadism in the primary care clinic. Prim Care. 2003;30:743-763. PubMed 
  11. Porst HP, Buvat J, red. Standard practice in sexual medicine. Oxford: Blackwell Publishing, 2006.
  12. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med 2016; 374: 611. pmid:26886521 PubMed 
  13. Resnick SM, et al. Testosterone treatment and cognitive function in older men with low testosterone and age-associated memory impairment. JAMA 2017; 317: 708. doi:10.1001/jama.2016.21044 DOI 
  14. Budoff MJ, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA 2017; 317: 708. doi:10.1001/jama.2016.21043 DOI 
  15. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482-92. PubMed 
  16. Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol 2017. pmid:28434676 PubMed 
  17. Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310: 1829-36 Journal of the American Medical Association 
  18. Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009; 54: 919-27. pmid:19712802 PubMed 
  19. Walker RF, Zakai NA, MacLehose RF, et al. Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism. JAMA Intern Med 2019. pmid:31710339 PubMed 
  20. Ayele HT, Brunetti VC, Renoux C, et al. Testosterone replacement therapy and the risk of venous thromboembolism: A systematic review and meta-analysis of randomized controlled trials. Thromb Res. 2021 Jan 6;199:123-131. PMID: 33486321 PubMed 
  21. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011; 34: 828-37. pmid:21386088 PubMed 
  22. Diem SJ, Greer NL, MacDonald R, et al. Efficacy and Safety of Testosterone Treatment in Men: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. Ann Intern Med. 2020. PMID: 31905375 PubMed 
  23. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001;111:261-269. PubMed 
  24. Pechersky AV, Mazurov VI, Semiglazov VF, Karpischenko AI, Mikhailichenko VV, Udintsev AV. Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int J Androl 2002;25:119-125. PubMed 
  25. Pharmacovigilance Risk Assessment Committee (PRAC). European Medicines Agency. PRAC review does not confirm increase in heart problems with testosterone medicines. 10/10/2014
  26. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89:5920-5926. PubMed 
  27. Tharu T, Saful M, Channa J, Suks M. Investigating the basis of sexual dysfunction during late-onset hypogonadism. F1000Research 2019. doi:10.12688/f1000research.16561.1 DOI